The legal action, filed in the United States District Court for the Southern District of New York, centers on claims that Regeneron executives maintained an overly optimistic outlook on the Phase III study while failing to disclose potential statistical flaws. The complaint highlights that slowing progression-free survival (PFS) event accrual was not adequately communicated to the market, leading to a sharp repricing of the stock when the underlying issues surfaced.
Regeneron Faces Class Action Over Fianlimab-Libtayo Trial Disclosures
A securities class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. on behalf of investors who purchased shares between August 1, 2025, and May 15, 2026. The complaint alleges that the company misled shareholders regarding the clinical trial risks associated with its Fianlimab-Libtayo combination therapy.
Regeneron shares experienced significant volatility following two key disclosures. On April 29, 2026, the company announced a protocol amendment to expand the patient population eligible for PFS analysis, causing the stock to fall approximately 6.2%. A deeper decline followed the May 15, 2026 announcement that the trial had failed to reach statistical significance for its primary endpoint. By the close of trading on May 18, the stock had dropped to $629.68, marking a total decline of $102.09 per share—or roughly 13.95%—from its April 28 closing price of $731.77. Lead plaintiff applications must be submitted to the court by September 14, 2026.
Comments (0)
No comments yet. Be the first!